US biopharmaceutical company Nanotherapeutics has selected GE Healthcare Life Sciences' FlexFactory to perform a central role in its Advanced Development and Manufacturing (NANO-ADM) Centre at Alachua, Florida. Construction of the NANO-ADM Centre began in October 2013 and is expected to be completed early in 2015.
The NANO-ADM Centre will fulfill a US Department of Defense contract awarded to Nanotherapeutics in April 2013 to develop biomedical countermeasures to protect and treat US military personnel against chemical, biological, radiological and nuclear attacks, in addition to protecting against outbreaks of naturally occurring, emerging and genetically engineered infectious diseases.
GE Healthcare has become part of a network of 16 partners, and has been closely involved from the inception of the project.
The firm says Nanotherapeutics’ adoption of its FlexFactory biomanufacturing platform and single-use technologies will help reduce commissioning time significantly and allow rapid reconfiguration of the facility for the manufacture of a range of products. GE will provide full training and support in process development to the NANO-ADM Centre staff, further accelerating set-up time.
'We are delighted to be playing a pivotal role in the establishment and set-up of Nanotherapeutics’ Advanced Development and Manufacturing Centre,' said Nigel Darby, Vice President Bioprocess and GE Officer.
'The wide-ranging and forward-looking criteria of this US Department of Defense contract demands a fast and responsive solution and the flexibility of our established FlexFactory manufacturing platform and the deep sector experience of our team will both be critical components in the success of the programme.'
